Zealand Pharma A/S

Zealand Pharma A/S's next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Zealand Pharma A/S has 69.39M shares outstanding.

As of June 30, 2026, Zealand Pharma A/S maintains a current ratio of 13.98, meaning it holds 14.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.28, indicating elevated leverage, while an interest coverage ratio of 88.09 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Zealand Pharma A/S posted a return on equity (ROE) of 16.30, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 12.93 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 14.83, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.07, useful for judging operating efficiency across full business cycles. The company generates approximately 1.40M in revenue per employee across its workforce of 444.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Zealand Pharma A/S recorded 13.26M in income tax expense. That works out to an effective tax rate of 3.49, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 379.84M, leaving 366.58M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Zealand Pharma A/S generated 621.32M in revenue and converted that into 366.58M in net income, yielding earnings per share of 5.19. EBITDA reached 319.05M, while operating income came in at 334.80M.

As of June 30, 2026, Zealand Pharma A/S holds 1.93B in cash and equivalents against 54.99M in total debt, resulting in a net debt position of -498.56M. Total book value stands at 2.41B, with working capital of 2.32B providing operational flexibility.

Zealand Pharma A/S produced -234.57M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -10.45M in capital expenditures, free cash flow totaled -245.02M - equivalent to -3.48 per share.

Over the twelve months ended June 30, 2026, Zealand Pharma A/S posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 53.88 and net profit margin of 59.00 provide insight into operational efficiency.